ClinicalTrials.gg
RecruitingNCT07222722Updated Oct 22, 2026

NIRS Monitoring in the NICU and AKI

An interventional study of NIRS Monitoring in Acute Kidney Injury (AKI) and Postnatal AKI, sponsored by NYU Langone Health. Recruiting at 1 site in United States. Open to participants aged 24 Weeks to 30 Weeks, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by NYU Langone Health · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Jun 2025, registered Oct 2025).
  • Started Jun 2025; still recruiting 1 year 4 months later.
Updated Oct 22, 2026Start date movedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
24 Weeks to 30 Weeks
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 370 studies in Acute Kidney Injury with a site in United States — 72 open to participants now, 88 under way, 9 of them phase 3. Acute Kidney Injury · United States.

Planned enrollment
93rd of 237
100 · median 67
Started
2025
with 21 others
No phase
106 of 370
25 open now
Primary completion
2027-07
later than 46 of 87 live
Registered
350th of 370
by date

Among the 370 studies in Acute Kidney Injury with a site in United States, this one is the 93rd largest by planned enrollment of the 237 interventional ones that give a count, is one of 22 that started in 2025, is one of 106 with no phase, reaches primary completion later than 46 of the 87 other live ones, and was the 350th registered.

Acute Kidney Injury

1,693 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.

Browse Acute Kidney Injury studies →

Open to participants now

72 of the 370 studies in Acute Kidney Injury with a site in United States are open now. Recruiting first, the newest first:

67 more — sign in →

All 72 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 229 Acute Kidney Injury studies recruiting now, 161 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.

This study: 24 Weeks to 30 Weeks · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 370 studies in Acute Kidney Injury with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this study is to describe the pattern of renal tissue oxygen saturation (SrSO2) using near-infrared spectroscopy (NIRS) in premature infants \<30 weeks gestational age. The secondary objective of this study is to evaluate prenatal and postnatal risk factors for acute kidney injury (AKI) in premature infants \<30 weeks gestational age. The investigators will also compare various rates of complications including death, length-of-stay, and prolonged duration of mechanical ventilation, among others.

03

Conditions studied

  • Acute Kidney Injury (AKI)
  • Postnatal AKI

Browse trials for

04

Who can participate

Ages eligible
24 Weeks to 30 Weeks
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Any neonate less than 30 weeks in gestational age
  • Willingness and capacity of both adult parents/guardians to sign consent

Exclusion criteria

Exclusion Criteria:

  • An infant with known congenital anomalies of the kidney (i.e., grade 4 or 5 vesicoureteral reflux (VUR), posterior urethral valves, moderate or severe hydronephrosis, autosomal recessive polycystic kidney disease (ARPKD), bilateral renal agenesis or dysplasia)
  • Age >30 weeks gestational age
  • Age \<24 weeks and \<500 grams (will be excluded due to sensitivity of skin in this vulnerable population).
  • Clinician's decision that NIRS is not suitable due to the patient's clinical condition
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    NICU patients born less than 30 weeks gestational age

    All patients included in the study will be assigned to receive NIRS monitoring.

    Device: NIRS Monitoring

Interventions

  • DeviceNIRS Monitoring

    The renal NIRS device is a non-invasive tool that uses near-infrared light to measure oxygen saturation various tissues. Renal NIRS sensors will be placed by 24 hours of the participants' admission.

06

What researchers measure

Primary outcomes

  1. Average NIRS Value (SrSO2)

    NIRS values measured as renal tissue oxygen saturation (SrSO2); measured continuously over first 7 days of life.

    Time frame: Up to Day-of-life 7

Secondary outcomes

  1. Serum Creatinine Values

    Time frame: Day-of-life 1, Day-of-life 3, Day-of-life 7, Day-of-life 14

  2. Average Urine Output

    Time frame: Up to Day of NICU Discharge (Approximately Day-of-life 7; subject to large individual variations)

  3. Length-of-Stay in NICU

    Time frame: Day of NICU Discharge (Approximately Day-of-life 7; subject to large individual variations)

  4. Duration of Non-Invasive Ventilation

    Time frame: Up to Day of NICU Discharge (Approximately Day-of-life 7; subject to large individual variations)

  5. Duration of Mechanical Ventilation

    Time frame: Up to Day of NICU Discharge (Approximately Day-of-life 7; subject to large individual variations)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The de-identified participant data from the final research dataset will be shared upon reasonable request beginning 9 to 36 months after publication or as required by a condition of awards or supporting agreements, provided the requesting investigator executes a data use agreement with NYU Langone Health. This instance of data sharing will also require separate IRB review as well as review from NYU Langone's Data Sharing Strategy Board (DSSB). Requests should be directed to: Jordan.nelson@nyulangone.org. The protocol and statistical analysis plan will be posted on Clinicaltrials.gov only as required by federal regulation or supporting awards and agreements.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.

Access criteria: The investigator who proposed to use the data will be granted access upon reasonable request. Requests should be directed to Jordan.nelson@nyulangone.org. To gain access, data requestors will need to sign a data access agreement. This instance of data sharing will also require separate IRB review as well as review from NYU Langone's DSSB.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Jul 2027, 25 months after the start.

Of 251 non-industry interventional studies with no phase under Acute Kidney Injury, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 44. This study's planned 25 months is close to that.

Counting every sponsor, half of 269 studies reached it within 26 months; a quarter within 12 and three quarters within 44.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 22, 2026: start Nov 2025 → Jun 2025, primary completion Apr 2026 → Jul 2027 and completion Apr 2026 → Jul 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2025
First posted
Oct 30, 2025
StartActual
Jun 24, 2025was Nov 2025
Primary completionEst.
Jul 31, 2027was Apr 2026
CompletionEst.
Jul 31, 2028was Apr 2026
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Nov 2025→Jun 24, 2025 (actual)
Oct 22, 2026
Primary completion
Apr 1, 2026→Jul 31, 2027
Oct 22, 2026
Study completion
Apr 1, 2026→Jul 31, 2028
Oct 22, 2026
Contact
Study contact changed: J•••@nyulangone.org · •••3664→s•••@nyulangone.org. See the current contact
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Start date Nov 2025→Jun 24, 2025 (now actual)
    Primary completion Apr 1, 2026→Jul 31, 2027
    Study completion Apr 1, 2026→Jul 31, 2028
    Contact Study contact changed: J•••@nyulangone.org · •••3664→s•••@nyulangone.org. See the current contact
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07222722
Lead sponsor
NYU Langone Health
Responsible party
Sponsor
First posted
Oct 30, 2025
Start date
Jun 24, 2025
Primary completion
Jul 31, 2027 (estimated)
Completion
Jul 31, 2028 (estimated)
Last update
Oct 22, 2026

Study contacts

Sourabh Verma, MD
Contact
sourabh.verma@nyulangone.org
Sourabh Verma, MD
principal investigator · NYU Langone Health

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion